Table 2 Comparison of the baseline characteristics of SCLC between patients in the IPF and no-IPF groups.

From: Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients

Characteristics

IPF

No-IPF

P-value

Number of patients

18

72

 

Age, years

70.4 ± 7.6

70.0 ± 6.9

0.828

Male

17 (94.4)

68 (94.4)

> 0.999

Ever-smoker

16 (100.0)

57 (95.0)

0.487

BMI, kg/m2

23.9 ± 2.7

23.3 ± 3.4

0.543

Cough

16 (88.9)

39 (57.4)

0.013

Dyspnea

13 (76.5)

30 (45.5)

0.022

PFT

FVC, % predicted

65.3 ± 13.4

73.3 ± 13.6

0.055

DLco, % predicted

46.1 ± 13.4

65.7 ± 18.1

< 0.001

TLC, % predicted

64.3 ± 13.5

82.5 ± 17.0

0.006

Stage

  

> 0.999

Limited

3 (16.7)

12 (16.7)

 

Extensive

15 (83.3)

60 (83.3)

 

Location of cancer (lobe)

  

0.111

Upper or middle

6 (33.3)

36 (54.5)

 

Lower

12 (66.7)

30 (45.5)

 
  1. Data are presented as mean ± SD or number (%), unless otherwise indicated.
  2. SCLC small cell lung cancer, IPF idiopathic pulmonary fibrosis, BMI body mass index, PFT pulmonary function test, FVC forced vital capacity, DLco diffusing capacity for carbon monoxide, TLC total lung capacity.
Back to article page